Loading…
Chemomab Therapeutics Ltd Is A Clinical-Stage Biotechnology Company, Focusing On The Discovery And Development Of Therapeutics For Fibrosis-Related Diseases With Large Unmet Needs. The Company'S Candidate, Cm-101, Is A Monoclonal Antibody That Targets Ccl24 And Was Shown To Interfere With The Underlying Biology Of Liver, Skin, And Lung Fibrosis Using A Novel And Differentiated Mechanism Of Action. Cm-101 Has Demonstrated The Potential To Treat Multiple Severe And Life-Threatening Fibrotic And Inflammatory Diseases.